Patient Protection in Cancer Chemotherapy

Schwartz, Stanley A.; Perry, Seymour

doi:10.1001/jama.1966.03110080063020

Cited by 51 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haynes and Hench were the first to use a mobile plastic film isolation unit, and showed a reduction in crossinfection in the treatment of burns (Haynes and Hench, 1965). Schwartz and Perry (1966) later demonstrated the suitability of the same plastic isolator for cancer patients undergoing intensive chemotherapy. The human maintenance isolation unit used here (Barnes et al, 1968d) was first tested with germ-free animals.…”

Section: Discussionmentioning

confidence: 99%

Care and observation of a germ-free neonate.

Barnes¹,

Bentovim²,

Hensman³

et al. 1969

Archives of Disease in Childhood

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Care and observation of a germ-free neonate.

Barnes¹,

Bentovim²,

Hensman³

et al. 1969

Archives of Disease in Childhood

View full text Add to dashboard Cite

“…By improving the efficacy of cisplatin‐based chemotherapy and minimizing the suffering caused by its side effects, this study contributes to the advancement of humanistic care for patients undergoing chemotherapy and brings attention to the field of chemotherapy protection (Scheme 1 ). 28 …”

Section: Introductionmentioning

confidence: 99%

A DNA nanostructure‐Hif‐1α inducer complex as novel nanotherapy against cisplatin‐induced acute kidney injury

Chen,

Xu,

Shi

et al. 2024

Cell Proliferation

View full text Add to dashboard Cite

Since its discovery in 1978, cisplatin‐based chemotherapy regimens have served a pivotal role in human cancer treatment, saving millions of lives. However, its high risk still poses a significant challenge for cisplatin‐induced acute kidney injury (AKI), which occurs in 30% of cisplatin‐treated patients. Unfortunately, no effective solution for preventing or managing this severe complication, which greatly impacts its clinical administration. Kidney is the main organ injured by cisplatin, and the injury is related to cisplatin‐induced cell apoptosis and DNA injury. Therefore, to achieve the safe use of cisplatin in tumour treatment, the key lies in identifying a kidney treatment that can effectively minimize cisplatin nephrotoxicity. Here, we successfully synthesized and applied a DNA‐nanostructure complex, named TFG, which contains tetrahedral framework nucleic acids (tFNAs) and FG‐4592, a novel Hif‐1α inducer. As cargo, TFG is composed entirely of DNA strands. It possesses low nephrotoxicity and renal aggregation properties while FG‐4592 is able to relieve renal injury by downregulating the apoptosis signal pathways. And it can relieve cisplatin‐induced renal injury when taken cisplatin treatment. This work aims to enhance chemotherapy protection in tumour patients by using TFG, a DNA‐based nanomedicines to kidney. This work has the potential to revolutionize the treatment of renal diseases, particularly drug‐induced kidney injury, leading to improved clinical outcomes.

show abstract

“…The antibiotics used for decontamination are administered orally and are not or only minimally absorbed from the digestive tract. The antibiotics employed for decontamination in man are sometimes selected on the basis of a sensitivity test (Gunn & Gould, 1965) but are often selected without prior information concerning the sensitivity pattern of the patient's microflora and are supplied in empirical dosages (Schwartz & Perry, 1966;Bodey, Loftis & Bowen, 1968;Preisler, Goldstein & Henderson, 1970). In our laboratory, decontamination of animals is always preceded by a sensitivity test on their faecal microflora (van de Waaij, de Vries & Lekkerkerk, 1970).…”

Section: Introductionmentioning

confidence: 99%

Oral dose and faecal concentration of antibiotics during antibiotic decontamination in mice and in a patient

Waaij

Vries

Altes

1974

J. Hyg.

View full text Add to dashboard Cite

In both mice and one patient, a similar correlation was found between the oral dose of a ;nonabsorbable' aminoglycoside antibiotic selected for antibiotic decontamination of the digestive tract and the resultant faecal concentration. In mice, absorption of the orally-given antibiotics could only be demonstrated in animals treated with extremely high doses of 1440 mg. per kg. body weight per day. Evidence of absorption of gentamycin was found to occur in a patient after doses as low as 70 mg. per kg. per day.

show abstract

Patient Protection in Cancer Chemotherapy

Cited by 51 publications

References 9 publications

Care and observation of a germ-free neonate.

Care and observation of a germ-free neonate.

A DNA nanostructure‐Hif‐1α inducer complex as novel nanotherapy against cisplatin‐induced acute kidney injury

Oral dose and faecal concentration of antibiotics during antibiotic decontamination in mice and in a patient

Contact Info

Product

Resources

About